Search

Displaying results 1581 - 1590 of 2430 in total
  1. Drug

    Fedratinib

    go.drugbank.com/drugs/DB12500
    ApprovedInvestigational

    Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis. It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval o...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  2. Drug

    Omaveloxolone

    go.drugbank.com/drugs/DB12513
    ApprovedInvestigational

    Omaveloxolone (RTA-408) is a semisynthetic oleanane triterpenoid with antioxidant and anti-inflammatory properties. Omaveloxolone acts as an activator of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcription factor that mit...

    Categories: Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 Substrates
  3. Drug

    Lobucavir

    go.drugbank.com/drugs/DB12531
    Investigational

    Lobucavir has been used in trials studying the treatment of HIV Infections and Cytomegalovirus Infections.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  4. Drug

    SAR-405838

    go.drugbank.com/drugs/DB12541
    Investigational

    SAR405838 has been used in trials studying the treatment of Neoplasm Malignant.

    Categories: P-glycoprotein substrates
  5. Drug

    Tradipitant

    go.drugbank.com/drugs/DB12580
    ApprovedInvestigational

    Tradipitant is a selective, high-affinity antagonist at human substance P/neurokinin-1 (NK-1) receptors.

    Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A Inducers
  6. Drug

    Etripamil

    go.drugbank.com/drugs/DB12605
    ApprovedInvestigational

    Etripamil is a nondihydropyridine, L-type calcium channel blocker. It is a fast-acting drug with a short duration of action. The nasal formulation of etripamil was first approved by the FDA on December 12, 2025 for the conversion of acut...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  7. Drug

    Bucindolol

    go.drugbank.com/drugs/DB12752
    Investigational

    Bucindolol has been investigated in Heart Failure.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates
  8. Drug

    Zoliflodacin

    go.drugbank.com/drugs/DB12817
    ApprovedInvestigational

    Gonorrhea, caused by Neisseria gonorrhoeae, presents a significant public health challenge due to increasing antimicrobial resistance. Zoliflodacin is a first-in-class spiropyrimidinetrione antibiotic designed to address this need by inh...

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  9. Drug

    Secnidazole

    go.drugbank.com/drugs/DB12834
    ApprovedInvestigational

    Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including DB00916 and DB00911, but displays improved oral absorption and a longer terminal elimination half-l...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsProducts: SECNIDAZOL 500 MG POLVO P RECONSTRUIR, SECNIDAZOL 750 MG POLVO P. RECOSTRUIR
  10. Drug

    Grapiprant

    go.drugbank.com/drugs/DB12836
    InvestigationalVet approved

    Grapiprant, also known as AT-001 and CJ-023, is a drug from the piprant class. These molecules were derived from acylsulfonamide and are characterized to be a novel series of para-N-acylaminomethylbenzoic acid known to be prostaglandin r...

    Categories: P-glycoprotein substrates